R Milroy
Overview
Explore the profile of R Milroy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grose D, Devereux G, Milroy R
Clin Lung Cancer
. 2011 Jul;
12(4):207-11.
PMID: 21726818
Introduction: Treatment and survival rates for patients with lung cancer in Scotland appear lower than in many other European countries. Five-year survival is quoted at 6% to 7% compared with...
2.
Evans T, Mansi J, Morgan D, Gyi K, Banham S, Milroy R
Oncol Rep
. 2011 May;
4(6):1337-41.
PMID: 21590250
Twenty-seven patients with non-small cell lung cancer were recruited into a phase II study of single-agent vinorelbine using a 25 mg/m(2) weekly dose schedule. All patients were inoperable (stage III...
3.
Tsim S, ODowd C, Milroy R, Davidson S
Respir Med
. 2010 Sep;
104(12):1767-74.
PMID: 20833010
Lung cancer remains the most common cause of cancer-related mortality in Scotland, accounting for 28.9% of all cancer deaths in 2007. (1) Current guidelines recommend assessment of patient fitness and...
4.
Buchanan D, Milroy R, Baker L, Thompson A, Levack P
Support Care Cancer
. 2009 Apr;
18(1):29-36.
PMID: 19350285
Introduction: Lung cancer is a disease of high symptom burden, major psychosocial impact and poor prognosis. Although diagnosis is individual, each patient operates within a social context. Patient perception of...
5.
Brown D, Milroy R, Preston T, McMillan D
J Clin Pathol
. 2006 Apr;
60(6):705-8.
PMID: 16644880
Background: The Glasgow Prognostic Score (GPS), an inflammation-based prognostic score formed from standard thresholds of C reactive protein (CRP) and albumin, has prognostic value in patients with advanced cancer. Little...
6.
Brown J, Thorpe H, Napp V, Fairlamb D, Gower N, Milroy R, et al.
J Clin Oncol
. 2005 Sep;
23(30):7417-27.
PMID: 16157935
Purpose: The Big Lung Trial (BLT) was a large, pragmatic trial to evaluate the addition of chemotherapy to primary treatment (ie, surgery, radical radiotherapy, or supportive care) in non-small-cell lung...
7.
Spiro S, Rudd R, Souhami R, Brown J, Fairlamb D, Gower N, et al.
Thorax
. 2004 Sep;
59(10):828-36.
PMID: 15454647
Background: In 1995 a meta-analysis of randomised trials investigating the value of adding chemotherapy to primary treatment for non-small cell lung cancer (NSCLC) suggested a small survival benefit for cisplatin-based...
8.
Waller D, Peake M, Stephens R, Gower N, Milroy R, Parmar M, et al.
Eur J Cardiothorac Surg
. 2004 Jun;
26(1):173-82.
PMID: 15200998
Objectives: The non-small cell lung cancer (NSCLC) meta-analysis suggested a survival benefit for cisplatin-based chemotherapy when given in addition to surgery, radical radiotherapy or 'best supportive care'. However, it included...
9.
Connolly C, Van Schil P, Milroy R, Braendli O, Prescott R
Eur Respir J
. 2003 Nov;
22(5):838-44.
PMID: 14621094
Outcome of lung cancer appears poorer in the UK than elsewhere in Europe. This may be due to a less aggressive approach in treatment. This study investigated whether clinicians' perceptions...
10.
Fergusson R, Thomson C, Brewster D, Brown P, Milroy R
Eur Respir J
. 2003 May;
21(4):606-10.
PMID: 12762343
Patients with lung cancer present to and are managed by a variety of clinicians. In this study the effect of involvement by a respiratory physician on the diagnosis, staging, treatment...